Iovance Biotherapeutics
American biopharmaceutical startup
IOVA Nasdaq
ISIN US4622601007 SEC CIK 1425205
Follow Iovance Biotherapeutics
Weekly email: filings, results
Revenue, last quarter
$121.5M
+80.1% vs same quarter last year
Net income
−$22.3M
+75.6% vs same quarter last year
EPS, diluted
−$0.05
+80% vs same quarter last year
Operating cash flow
−$4.5M
+94.3% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $263.5M | −$391M |
| FY24 | $164.1M | −$372.2M |
| FY23 | $1.2M | −$444M |
| FY22 | - | −$395.9M |
| FY21 | - | −$342.3M |
| FY20 | - | −$259.6M |
| FY19 | - | −$197.6M |
| FY18 | $0 | −$123.6M |
| FY17 | $0 | −$92.1M |
| FY16 | $0 | −$52.9M |
| FY15 | $0 | −$27.7M |
| FY14 | $0 | −$12M |
| FY13 | $0 | −$25.4M |
| FY12 | $0 | −$3.3M |
| FY11 | $0 | −$25.7M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 34.3% | −153.1% | −148.4% |
| FY24 | 43.2% | −240.9% | −226.9% |
| FY23 | 13.1% | −38735% | −37342.3% |
| FY22 | - | - | - |
| FY21 | - | - | - |
| FY20 | - | - | - |
| FY19 | - | - | - |
| FY18 | - | - | - |
| FY17 | - | - | - |
| FY16 | - | - | - |
| FY15 | - | - | - |
| FY14 | - | - | - |
| FY13 | - | - | - |
| FY12 | - | - | - |
| FY11 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$336.2M |
| FY24 | −$364M |
| FY23 | −$384.1M |
| FY22 | −$313.2M |
| FY21 | −$265.5M |
| FY20 | −$251.9M |
| FY19 | −$165.8M |
| FY18 | −$102.4M |
| FY17 | −$79.7M |
| FY16 | −$34.2M |
| FY15 | −$19.5M |
| FY14 | $7M |
| FY13 | −$3.7M |
| FY12 | −$2.2M |
| FY11 | −$6.2M |
- Iovance Biotherapeutics
- Healthcare median
Show the numbers
| Year | Iovance Biotherapeutics | Healthcare median |
|---|---|---|
| FY25 | −148.4% | −30.6% |
| FY24 | −226.9% | −47% |
| FY23 | −37342.3% | −58% |
| FY22 | - | −80.4% |
| FY21 | - | −71.9% |
| FY20 | - | −62.2% |
| FY19 | - | −46.3% |
| FY18 | - | −49.6% |
| FY17 | - | −45.9% |
| FY16 | - | −36% |
| FY15 | - | −38.4% |
| FY14 | - | −35.5% |
| FY13 | - | −37.1% |
| FY12 | - | −29.1% |
| FY11 | - | −27.9% |